Platelet biology and implications for antiplatelet therapy in atherothrombotic disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 4, 2011, Pages 371-380

  Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ADP; hemostasis; PAR 1; platelet; thrombin; thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VORAPAXAR;

ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; ATHEROTHROMBOTIC DISEASE; BLEEDING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HEMOSTASIS; HUMAN; INFLAMMATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SYNCOPE; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOSIS PREVENTION; URIC ACID BLOOD LEVEL;

BLOOD PLATELETS; HEMOSTASIS; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; THROMBOSIS;

EID: 80052750276     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610373366     Document Type: Article

References (103)

1. Brass LF Thrombin and platelet activation. Chest. 2003 ; 124 (3suppl). 18S - 25S. (Pubitemid 37128432)
2. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007 ; 357 (24). 2482-2494.
3. Varga-Szabo D., Pleines I., Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008 ; 28 (3). 403-412.
4. Ruggeri ZM Structure and function of von Willebrand factor. Thromb Haemost. 1999 ; 82 (2). 576-584.
5. Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol. 1986 ; 63 (4). 681-691. (Pubitemid 16033606)
6. Sugiyama T., Okuma M., Ushikubi F., Sensaki S., Kanaji K., Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood. 1987 ; 69 (6). 1712-1720. (Pubitemid 17091630)
7. Santoro SA Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell. 1986 ; 46 (6). 913-920. (Pubitemid 16027939)
8. Nieswandt B., Watson SP Platelet-collagen interaction: is GPVI the central receptor ? Blood. 2003 ; 102 (2). 449-461. (Pubitemid 36841960)
9. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006 ; 99 (12). 1293-1304. (Pubitemid 44949665)
10. Coughlin SR Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005 ; 3 (8). 1800-1814. (Pubitemid 41716567)
11. Brummel KE, Paradis SG, Butenas S., Mann KG Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002 ; 100 (1). 148-152. (Pubitemid 35177440)
12. Mann KG Thrombin formation. Chest. 2003 ; 124 (3suppl). 4S - 10S. (Pubitemid 37128430)
13. Lord ST Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol. 2007 ; 14 (3). 236-241. (Pubitemid 46597609)
14. Ni H., Denis CV, Subbarao S., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000 ; 106 (3). 385-392. (Pubitemid 30655638)
15. Kulkarni S., Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000 ; 105 (6). 783-791. (Pubitemid 30164117)
16. Phillips DR, Nannizzi-Alaimo L., Prasad KS Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling. Thromb Haemost. 2001 ; 86 (1). 246-258. (Pubitemid 32663955)
17. Wasserman EJ, Shipley NM Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006 ; 73 (1). 431-439. (Pubitemid 43192232)
18. Virmani R., Kolodgie FD, Burke AP, Farb A., Schwartz SM Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000 ; 20 (5). 1262-1275. (Pubitemid 30262927)
19. Mizuno K., Satomura K., Miyamoto A., et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992 ; 326 (5). 287-291.
20. Rauch U., Osende JI, Fuster V., Badimon JJ, Fayad Z., Chesebro JH Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001 ; 134 (3). 224-238. (Pubitemid 32113325)
21. Théroux P., Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998 ; 97 (12). 1195-1206. (Pubitemid 28152893)
22. Collet JP, Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003 ; 108 (4). 391-394. (Pubitemid 36935529)
23. Montalescot G., Bal-dit-Sollier C., Chibedi D., et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003 ; 91 (8). 925-930. (Pubitemid 36398522)
24. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE trial. Circulation. 1998 ; 98 (4). 294-299. (Pubitemid 28348050)
25. Ray KK, Morrow DA, Gibson CM, Murphy S., Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J. 2005 ; 26 (5). 440-446. (Pubitemid 40314759)
26. Fabre JE, Nguyen M., Latour A., et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999 ; 5 (10). 1199-1202. (Pubitemid 29474427)
27. Dorsam RT, Kunapuli SP Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004 ; 113 (3). 340-345. (Pubitemid 38544175)
28. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002 ; 88 (3). 488-494. (Pubitemid 35021609)
29. Andre P., Delaney SM, LaRocca T., et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003 ; 112 (3). 398-406. (Pubitemid 38063768)
30. FitzGerald GA Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991 ; 68 (7). 11B - 15B.
31. Patscheke H., Hornberger W., Zehender H. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. Z Kardiol. 1990 ; 79 (suppl 3). 151-154.
32. Jurk K., Kehrel BE Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005 ; 31 (4). 381-392. (Pubitemid 41362342)
33. Xu WF, Andersen H., Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998 ; 95 (12). 6642-6646. (Pubitemid 28278033)
34. Vu TK, Hung DT, Wheaton VI, Coughlin SR Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991 ; 64 (6). 1057-1068. (Pubitemid 121001193)
35. Andersen H., Greenberg DL, Fujikawa K., Xu W., Chung DW, Davie EW Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999 ; 96 (20). 11189-11193. (Pubitemid 29487356)
36. Henriksen RA, Hanks VK PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol. 2002 ; 22 (5). 861-866. (Pubitemid 34517802)
37. Nylander S., Mattsson C., Ramstrom S., Lindahl TL Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol. 2004 ; 142 (8). 1325-1331. (Pubitemid 39178886)
38. Vassallo RR Jr Kieber-Emmons T., Cichowski K., Brass LF Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem. 1992 ; 267 (9). 6081-6085.
39. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003 ; 304 (2). 855-861. (Pubitemid 36152366)
40. Kato Y., Kita Y., Hirasawa-Taniyama Y., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003 ; 473 (2-3). 163-169. (Pubitemid 36929880)
41. Vandendries ER, Hamilton JR, Coughlin SR, Furie B., Furie BC Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007 ; 104 (1). 288-292. (Pubitemid 46068024)
42. Landis RC Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007 ; 21 (1). 103-113. (Pubitemid 46164771)
43. Suh TT, Holmback K., Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995 ; 9 (16). 2020-2033.
44. Gawaz M., Langer H., May AE Platelets in inflammation and atherogenesis. J Clin Invest. 2005 ; 115 (12). 3378-3384. (Pubitemid 43121822)
45. May AE, Seizer P., Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol. 2008 ; 28 (3). s5 - s10.
46. Henn V., Slupsky JR, Gräfe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 ; 391 (6667). 591-594. (Pubitemid 28157601)
47. Chakrabarti S., Varghese S., Vitseva O., Tanriverdi K., Freedman JE CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005 ; 25 (11). 2428-2434. (Pubitemid 41552666)
48. Krötz F., Sohn HY, Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002 ; 100 (3). 917-924. (Pubitemid 34832618)
49. Lambert MP, Sachais BS, Kowalska MA Chemokines and thrombogenicity. Thromb Haemost. 2007 ; 97 (5). 722-729. (Pubitemid 46779957)
50. von Hundelshausen P., Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007 ; 100 (1). 27-40. (Pubitemid 46066771)
51. von Hundelshausen P., Koenen RR, Sack M., et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005 ; 105 (3). 924-930. (Pubitemid 40170856)
52. Dixon DA, Tolley ND, Bemis-Standoli K., et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest. 2006 ; 116 (10). 2727-2738. (Pubitemid 44511636)
53. Simon DI, Chen Z., Xu H., et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000 ; 192 (2). 193-204. (Pubitemid 30470302)
54. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 ; 330 (18). 1287-1294. (Pubitemid 24129964)
55. Schulman SP Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA. 2004 ; 292 (15). 1875-1882. (Pubitemid 40169299)
56. Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 (7329). 71-86.
57. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 ; 309 (7). 396-403.
58. Popma JJ, Ohman EM, Weitz J., Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001 ; 119 (1suppl). 321S - 336S. (Pubitemid 32154208)
59. Schwartz L., Bourassa MG, Lespérance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988 ; 318 (26). 1714-1719.
60. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 ; 308 (6921). 81-106.
61. Cattaneo M. New P. 2Y(12) inhibitors. Circulation. 2010 ; 121 (1). 171-179.
62. Schomig A., Neumann FJ, Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 ; 334 (17). 1084-1089. (Pubitemid 26120185)
63. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 ; 339 (23). 1665-1671. (Pubitemid 28550691)
64. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 ; 348 (9038). 1329-1339.
65. Bhatt DL, Flather MD, Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 ; 49 (19). 1982-1988. (Pubitemid 46694290)
66. Bhatt DL, Fox KA, Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354 (16). 1706-1717.
67. Yusuf S., Zhao F., Mehta SR, Chrolavicius S., Tognoni G., Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345 (7). 494-502. (Pubitemid 32758501)
68. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288 (19). 2411-2420. (Pubitemid 35340537)
69. Mehta SR, Yusuf S., Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358 (9281). 527-533. (Pubitemid 32772726)
70. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 ; 366 (9497). 1607-1621.
71. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 ; 352 (12). 1179-1189. (Pubitemid 40397259)
72. Metha S. CURRENT OASIS 7: a 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Presented at: European Society of Cardiology (ESC) 2009 Congress; August 29-September 2, 2009 ; Barcelona, Spain.
73. Wiviott SD, Braunwald E., McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20). 2001-2015. (Pubitemid 350106708)
74. Wallentin L., Varenhorst C., James S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 ; 29 (1). 21-30.
75. Angiolillo DJ, Fernández-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004 ; 25 (21). 1903-1910. (Pubitemid 39452607)
76. Angiolillo DJ, Shoemaker SB, Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007 ; 115 (6). 708-716. (Pubitemid 46294761)
77. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008 ; 51 (14). 1404-1411. (Pubitemid 351447314)
78. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006 ; 48 (7). 1339-1345. (Pubitemid 44436814)
79. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 ; 111 (20). 2560-2564. (Pubitemid 40740853)
80. L'Allier PL, Ducrocq G., Pranno N., et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol. 2008 ; 51 (11). 1066-1072. (Pubitemid 351374773)
81. Lotrionte M., Biondi-Zoccai GG, Agostoni P., et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007 ; 100 (8). 1199-1206.
82. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006 ; 48 (5). 931-938. (Pubitemid 44292463)
83. Montalescot G., Wiviott SD, Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 ; 373 (9665). 723-731.
84. Wiviott SD, Braunwald E., Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008 ; 118 (16). 1626-1636.
85. Wiviott SD, Braunwald E., McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 ; 371 (9621). 1353-1363.
86. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. 2008 ; 5 (12). 766-780.
87. Husted S., Emanuelsson H., Heptinstall S., Sandset PM, Wickens M., Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006 ; 27 (9). 1038-1047.
88. Boersma E., Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 ; 359 (9302). 189-198. (Pubitemid 34113814)
89. Simoons ML Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 ; 357 (9272). 1915-1924. (Pubitemid 32568331)
90. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003 ; 108 (14). 1682-1687. (Pubitemid 37243654)
91. Krasopoulos G., Brister SJ, Beattie WS, Buchanan MR Aspirin ''resistance'' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 ; 336 (7637). 195-198. (Pubitemid 351212675)
92. Angiolillo DJ, Fernández-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 ; 49 (14). 1505-1516. (Pubitemid 46517957)
93. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention :
94. results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001 ; 103 (21). 2572-2578.
95. Kuliczkowski W., Witkowski A., Polonski L., et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009 ; 30 (4). 426-435.
96. Collet JP, Hulot JS, Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 ; 373 (9660). 309-317.
97. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 ; 360 (4). 354-362.
98. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2 009; 360 (4). 363-375.
99. Becker RC, Moliterno D., Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 ; 373 (9667). 919-928.
100. Goto S., Yamaguchi T., Ikeda Y., Kato K., Yamaguchi H., Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010 ; 17 (2). 156-164.
101. Shinohara Y., Goto S., Shimizu K., Jensen P. A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int J Stroke. 2008 ; 3 (suppl1). 139 ; ; Abstract PO101-193.
102. The TRACER Executive and Steering Committees. The Thombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: study design and rationale. Am Heart J. 2009 ; 158 (3). 327-334.
103. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009 ; 158 (3). 335-341.